Chronic Lymphocytic Leukemia
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the…
Date: 22nd March 2024
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who…
Date: 7th December 2023
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…
Date: 1st December 2023
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent…
Date: 29th June 2023
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 7th June 2023
The current status of CAR-T therapy in CLL and challenges in this space
In recent years, novel immunotherapies, including CAR-T cell therapy, have greatly improved treatment options for patients with hematological malignancies. Although CAR-T…
Date: 3rd March 2023
CLL highlights at ASH 2022: clinical trial updates, novel BTK inhibitors & combination therapy
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 9th January 2023
The importance of genomic testing in CLL and its role in clinical decision-making
Chronic lymphocytic leukemia (CLL) remains a challenging hematological malignancy to treat, and genomic testing has become increasingly important in this…
Date: 2nd December 2022
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
The treatment landscape of chronic lymphocytic leukemia (CLL) has transformed over the years with the increased use of Bruton’s tyrosine…
Date: 25th November 2022
The promise of CAR-T therapy in CLL and challenges in the field
The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents,…
Date: 31st August 2022
Updates in lymphoma and CLL treatment in the UK
In recent years, there have been many advances in the treatment of lymphoma and chronic lymphocytic leukemia (CLL) in the…
Date: 17th June 2022
ASH 2021: highlights in CLL clinical trials
Treatments such as ibrutinib and venetoclax, which target the Bruton tyrosine kinase (BTK) pathway and the B-cell lymphoma 2 (BCL-2)…
Date: 18th February 2022